Abstract 832P
Background
Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.
Methods
1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.
Results
The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.
Conclusions
The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1182P - Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
Presenter: Praful Ravi
Session: Poster session 09
1183P - Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
Presenter: Christina Dilaveri
Session: Poster session 09
1184P - Early real-world experience with positive multi-cancer early detection (MCED) test cases and negative initial diagnostic work-up
Presenter: Candace Westgate
Session: Poster session 09
1185P - Clinical applications of a novel blood-based fragmentomics assay for lung cancer detection
Presenter: Marc Siegel
Session: Poster session 09
1186P - SmartCS-LPLLM: Enhancing early cancer detection through ctDNA methylation analysis leveraging large language models
Presenter: Li Chao
Session: Poster session 09
1187P - Molecular diagnosis of lung cancer via ctDNA and ctRNA detection on bronchoscopic fluid specimens from 31 patients: A retrospective analysis
Presenter: Vincent Fallet
Session: Poster session 09
1188P - Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
Presenter: Sana Raoof
Session: Poster session 09
1189P - Cancer genome interpreter: A data-driven tool for tumor mutation interpretation
Presenter: Santiago Demajo
Session: Poster session 09
1190P - Circulating tumor DNA from the tumor-draining pulmonary vein as a biomarker in resected non-small cell lung cancer
Presenter: Raphael Werner
Session: Poster session 09
1191P - Efficient lung cancer stage prediction and outcome informatics with Bayesian deep learning and MCMC method
Presenter: Maria Gkotzamanidou
Session: Poster session 09